Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NRXP
SELLREMOVENRx Pharmaceuticals, Inc. · Healthcare · United States · $170M · Avg Vol: $5M/d
NRx Pharmaceuticals is a speculative micro-cap biotech with high cash burn and binary clinical trial risks, violating our quality compounder principles.
COMPANY DESCRIPTION
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for central nervous system disorders and life-threatening inflammatory diseases. The company's lead pipeline candidates target suicidal depression, bipolar depression, and acute respiratory failure. NRx leverages proprietary scientific discoveries to address high-barrier medical niches with significant unmet clinical needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1.2M | — |
| EPS | -0.95 | -0.78 | -0.80 | -1.34 | — |
| Shares | 42.8M | 42.8M | 42.8M | 31.7M | -25.9% |
| Debt | 10.5M | 9.2M | 6.6M | 0.6M | -60.9% |
| Equity | 7.4M | -11.7M | -23.2M | -15.9M | — |
| Op CF | -39.8M | -21.7M | -10.6M | -14.1M | — |
| Inv CF | -10,000 | -3,000 | 0 | -2.8M | — |
| Fin CF | 32.2M | 6.2M | 7.5M | 23.3M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NRXP are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NRXP | NRx Pharmaceuticals, Inc.(you) | $170M | 30 | SELL |
| ANTX | AN2 Therapeutics, Inc. | $191M | 33 | SELL |
| CNTN | Canton Strategic Holdings, Inc. | $235M | 30 | SELL |
| ACOG | Alpha Cognition Inc. Common Stock | $152M | 25 | SELL |
| KPTI | Karyopharm Therapeutics Inc. | $202M | 34 | SELL |
| HURA | TuHURA Biosciences, Inc. | $167M | 23 | SELL |
| ALXO | ALX Oncology Holdings Inc. | $212M | 27 | SELL |
| CDXS | Codexis, Inc. | $228M | 27 | SELL |
| MGNX | MacroGenics, Inc. | $257M | 31 | SELL |
| FATE | Fate Therapeutics, Inc. | $247M | 28 | SELL |
Peer medians: ROE -23.5% · P/E 25.2x · Gross margin 44.3%